作者: Javier Leon , Maria G Cortiguera , Ana Batlle-López , Marta Albajar , M. Dolores Delgado
DOI: 10.2147/BLCTT.S60495
关键词:
摘要: MYC is a transcription factor that involved in the expression of many genes. Deregulated found about half human tumors, being more prevalent hematologi- cal neoplasms. Deregulation mechanisms include chromosomal translocation (particularly lymphoma), amplification, and hyperactivation transcription. Here we review involvement major types leukemia lymphoma. rearrangements appear all Burkitt lymphomas are common other lymphoma types, whereas acute lymphoblastic leukemia, myeloid lymphoproliferative, myeloproferative diseases, they less frequent. However, overexpression present hematological malignancies often correlates with worse prognosis. Data leukemia-derived cells animal models lymphomagenesis leukemogenesis suggest would be good therapeutic target. Several MYC-directed therapies have been assayed preclinical settings even clinical trials. First, peptides small molecules interrupt MYC-MAX interaction impair MYC- mediated tumorogenesis several mouse solid although not yet models. Second, there number inhibiting heterodimers DNA, still research phase. Third, inhibitors via inhibition BRD4 (a reader acetylated histones) shown to control growth MYC-transformed used clinic Finally, promising MYC-mediated synthetic lethal approaches